EGFR and pancreatic neoplasm: This construct combines the well-characterized RGD peptide with GE11, a non-mitogenic peptide ligand for EGFR, allowing for simultaneous targeting of integrins and EGFR, both of which are implicated in pancreatic cancer progression and resistance to therapy.